Global investment firm Carlyle and Inova, a software provider for the biopharma industry, have announced a long-term funding partnership to accelerate growth, fund product innovation and M&A initiatives.
Carlyle is investing EUR60 million and will become Inova’s largest shareholder under the deal, while Management and historic investor NextStage AM have reaffirmed their strong commitment.
Headquartered in Lyon, France, with international offices in New York, Denver, and Tokyo, Inova is a market-leading software platform specifically dedicated to the life sciences industry, enabling pharmaceutical and biotech companies to collaborate on workstreams across their organizations. The company supports more than 150 global clients, including many of the world’s largest pharmaceutical companies, and is at the forefront of digital transformation in biopharma collaborations. Inova’s flagship product, ‘Inova Enterprise’, serves as a collaborative tool used to manage all processes related to outsourced innovation to laboratories and biotechs, enabling customers to source leads, execute transactions, manage alliances and virtual events.
Leveraging its significant experience across Technology and Healthcare, Carlyle will support Inova in entering its next phase of growth. The investment thesis is based on accelerating Inova’s international expansion, including strengthening its presence in China and the US, investing in the company’s innovative product suite and highly differentiated platform as well as strategic acquisitions.
Read more/Source: Private Equity Wire
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.